Table 5.

Minimum reporting recommendations for future studies

1. Presence of cirrhosis and Child Pugh score at baseline

2. Baseline tumor burden and median AFP prior to HCC treatment

3. Number of prior HCC recurrences

4. Types of HCC treatment leading to complete response

5. Confirmation of HCC complete response immediately preceding DAA therapy

6. Time from HCC treatment to DAA initiation

7. Time from last HCC complete response assessment to HCC recurrence

8. HCC surveillance protocol and adherence

9. Tumor burden at time of recurrence, treatment of recurrence, and response to treatment

10. Predictors of HCC recurrence after DAA therapy